The GNAS1 T393C polymorphism predicts survival in patients with advanced squamous cell carcinoma of the larynx

Laryngoscope

Volumn 118, Issue 12, 2008, Pages 2172-2176

  Lehnerdt, Goetz F ^a   Franz, Peter ^a   Winterh, Sebastian ^a   Bankfalvi, Agnes ^a   Grehl, Sara ^b   Lang, Stephan ^a,b   Schmid, Kurt W ^a,b   Siffert, Winfried ^b   Jahnke, Klaus ^a,b   Frey, Ulrich H ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

G s; G protein; Larynx carcinoma; Polymorphism; Prognostic marker; Signal transduction; SNP; T393C

Indexed keywords

CYTOSINE; PARAFFIN; THIOURACIL; GNAS PROTEIN, HUMAN; STIMULATORY GUANINE NUCLEOTIDE BINDING PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER RELAPSE; CANCER STAGING; CANCER SURVIVAL; CAUSE OF DEATH; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATIONAL STUDY; DISEASE FREE SURVIVAL; DNA DETERMINATION; FEMALE; FOLLOW UP; G ALPHA S GENE; GENE DOSAGE; GENE FREQUENCY; GENETIC CORRELATION; GENOTYPE; GLOTTIS; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LARYNX CANCER; MAJOR CLINICAL STUDY; MALE; ONCOGENE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; SURVIVAL TIME; TUMOR LOCALIZATION; ALLELE; GENETICS; KAPLAN MEIER METHOD; LARYNX TUMOR; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; POLYMERASE CHAIN REACTION; PROPORTIONAL HAZARDS MODEL;

AGED; ALLELES; CARCINOMA, SQUAMOUS CELL; FEMALE; GENOTYPE; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; KAPLAN-MEIERS ESTIMATE; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; POLYMERASE CHAIN REACTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 58149342135     PISSN: 0023852X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MLG.0b013e318185793ds     Document Type: Article

References (23)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Murray T., Thun MJ. Cancer statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Hoffman HT, Porter K., Karnell LH, et al. Laryngeal cancer in the United States: changes in demographics, patterns of care, and survival. Laryngoscope 2006; 116 (9 pt 2 suppl 111): 1-13.
3. Frey UH, Eisenhardt A., Lummen G., Rubben H., Jockel KH, Schmid KW, Siffert W. The T393C polymorphism of the G alpha s gene (GNAS1) is a novel prognostic marker in bladder cancer. Cancer Epidemiol Biomarkers Preu 2005; 14:871-877.
4. Frey UH, Alakus H., Wohlschlaeger J., et al. GNAS1 T393C polymorphism and survival in patients with sporadic colorectal cancer. Clin Cancer Res 2005; 11:5071-5077.
5. Frey UH, Lummen G., Jager T., et al. The GNAS1 T393C polymorphism predicts survival in patients with clear cell renal cell carcinoma. Clin Cancer Res 2006; 12 (3 pt 1): 759-763.
6. Lehnerdt G., Franz P., Zaqoul A., et al. Overall and relapse-free survival in oro-and hypopharyngeal squamous cell carcinoma are associated with genotypes of the T393C polymorphism of the GNAS1 gene. J Clin Cancer Res 2008; 14: 1753-1758.
7. Daaka Y., Luttrell LM, Lefkowitz RJ. Switching of the coupling of the beta2-adrenergic receptor to different G proteins by protein kinase A. Nature 1997; 390:88-91.
8. Krumins AM, Barber R. Examination of the effects of increasing Gs protein on beta2-adrenergic receptor, Gs, and adenylyl cyclase interactions. Biochem Pharmacol 1997; 54: 61-72.
9. Yang X., Lee FY Sr, Wand GS. Increased expression of Gs (alpha) enhances activation of the adenylyl cyclase signal transduction cascade. Mol Endocrinol 1997; 11:1053-1061.
10. Dumaz N., Light Y., Marais R. Cyclic AMP blocks cell growth through Raf-1-dependent and Raf-1-independent mechanisms. Mol Cell Biol 2002; 22:3717-3728.
11. Dumaz N., Hayward R., Martin J., et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res 2006; 66:9483-9491.
12. Duan J., Wainwright MS, Comeron JM, Saitou N., Sanders AR, Gelernter J., Gejman PV. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum Mol Genet 2003; 12:205-216.
13. Tierney MJ, Medcalf RL. Plasminogen activator inhibitor type 2 contains mRNA instability elements within exon 4 of the coding region. Sequence homology to coding region instability determinants in other mRNAs. J Biol Chem 2001; 276:13675-13684.
14. Siffert W., Forster P., Jockel KH, et al. Worldwide ethnic distribution of the G protein beta3 subunit 825T allele and its association with obesity in Caucasian, Chinese, and Black African individuals. J Am Soc Nephrol 1999; 10: 1921-1930.
15. Lehnerdt GF, Franz P., Zaqoul A., et al. Overall and relapsefree survival in oropharyngeal and hypopharyngeal squamous cell carcinoma are associated with genotypes of T393C polymorphism of the GNAS1 gene. Clin Cancer Res 2008; 14:1753-1758.
16. Otterbach F., Callies R., Frey UH, et al. The T393C polymorphism in the gene GNAS1 of G protein is associated with survival of patients with invasive breast carcinoma. Breast Cancer Res Treat 2007; 105:311-317.
17. Schmitz KJ, Lang H., Frey UH, et al. GNAS1T393C polymorphism is associated with clinical course in patients with intrahepatic cholangiocarcinoma. Neoplasia 2007; 9: 159-165.
18. Harry A., Chen Y., Magnusson R., Iyengar R., Weng G. Differential regulation of adenylyl cyclases by Galphas. J Biol Chem 1997; 272:19017-19021.
19. +controiled activation of Ras and extracellular signalregulated kinases by Gs-coupled receptors. J Biol Chem 2004; 279:46497-46508.
20. Kiermayer S., Biondi RM, Imig J., Plotz G., Haupenthal J., Zeuzem S., Piiper A. Epac activation converts cAMP from a proliferative into a differentiation signal in PC 12 cells. Mol Biol Cell 2005; 16:5639-5648.
21. Peyssonnaux C., Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell 2001; 93:53-62.
22. Kelland LR, Sharp SY, Rogers PM, Myers TG, Workman P. DT-diaphorase expression and tumor cell sensitivity to 17-allylamino, 17- demethoxygeldanamycin, an inhibitor of heat shock protein 90. J Natl Cancer Inst 1999; 91: 1940-1949.
23. Yin X., Zhang H., Burrows F., Zhang L., Shores CG. Potent activity of a novel dimeric heat shock protein 90 inhibitor against head and neck squamous cell carcinoma in vitro and in vivo. Clin Cancer Res 2005; 11:3889-3896.